Alnylam Pharmaceuticals (NASDAQ:ALNY) has filed a marketing applicationin Europe seeking approval of RNAi therapeutic givosiran for the treatment of acute hepatic porphyria, a group of four rare inherited liver disorders characterized by intense abdominal pain over a period of one-to-two weeks.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.